Evidence map›Paper›PMID 32150577›Full record

ArticlePloS one2020

Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.

Javier Lozano-Gerona, Aida Oliván-Viguera, Pablo Delgado-Wicke, Vikrant Singh, Brandon M Brown, Elena Tapia-Casellas, Esther Pueyo, Marta Sofía Valero, Ángel-Luis Garcia-Otín, Pilar Giraldo and 11 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 3 countries.

Javier Lozano-GeronaInstituto Aragonés de Ciencias de la Salud (IACS) y Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain.
Aida Oliván-VigueraBiosignal Interpretation and Computational Simulation (BSICoS), Aragón Institute of Engineering Research (I3A), Univ. of Zaragoza, Zaragoza, Spain.ORCID 0000-0001-5348-924X
Pablo Delgado-WickeDepartamento de Biología, Facultad de Ciencias, UAM, Madrid, Spain.
Vikrant SinghDept. of Pharmacology, University of California, Davis, CA, United States of America.
Brandon M BrownDept. of Pharmacology, University of California, Davis, CA, United States of America.
Elena Tapia-CasellasScientific and Technical Service, Aragónese Center for Biomedical Research, Univ. of Zaragoza, Zaragoza, Spain.
Esther PueyoBiosignal Interpretation and Computational Simulation (BSICoS), Aragón Institute of Engineering Research (I3A), Univ. of Zaragoza, Zaragoza, Spain.
Marta Sofía ValeroDept. of Pharmacology and Physiology, Univ. of Zaragoza, Huesca, Spain.
Ángel-Luis Garcia-OtínInstituto Aragonés de Ciencias de la Salud (IACS) y Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain.ORCID 0000-0002-5123-2480
Pilar GiraldoSpanish Foundation for the Study and Treatment of Gaucher Disease and other Lysosomal Disorders (FEETEG), Zaragoza, Spain.
Edgar Abarca-LachenUniversidad San Jorge, Faculty of Health Sciences, Villanueva de Gállego, Spain.
Joaquín C SurraDepartamento de Producción Animal y Ciencia de los Alimentos, CIBER-obn, Univ. of Zaragoza, Zaragoza, Spain.
Jesús OsadaDepartamento Bioquímica y Biología Molecular y Celular (CIBEROBN), Facultad de Veterinaria, Univ. of Zaragoza, Zaragoza, Spain.
Kirk L HamiltonDept. of Physiology, School of Biomedical Sciences, Univ. of Otago, Dunedin, New Zealand.
Siba P RaychaudhuriDepartment of Medicine and Dermatology, School of Medicine UC Davis and VA Sacramento Medical Center University of California, Mather, California, United States of America.
Miguel MarigilDept. of Pathology, Hospital San Jorge, Huesca, Spain.
Ángeles JuarranzDepartamento de Biología, Facultad de Ciencias, UAM, Madrid, Spain.
Heike WulffDept. of Pharmacology, University of California, Davis, CA, United States of America.
Hiroto MiuraDept. of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV, United States of America.
Yolanda GilaberteDept. of Dermatology, Univ. Hospital Miguel Servet, IIS Aragón, Zaragoza, Spain.
Ralf KöhlerInstituto Aragonés de Ciencias de la Salud (IACS) y Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain.ORCID 0000-0001-9563-2913
Universidad de Zaragoza · ESUniversity of California, Davis · USInstituto de Investigación Sanitaria Aragón · ESFundacion Agencia Aragonesa para la Investigacion y el Desarrollo · ESHospital General San Jorge · ESHospital Universitario Miguel Servet · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESUniversidad Autónoma de Madrid · ESUniversidad San Jorge · ESUniversity of California Davis Medical Center · USUniversity of Nevada, Reno · USUniversity of Otago · NZ

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
STRETCH DEPENDENT POTASSIUM CHANNEL REGULATION IN OVERACTIVE BLADDERP20RR018751 · NCRR · UNIVERSITY OF NEVADA RENO · PI RO, SEUNGIL · 2003 to 2011
$17.3M
UC Davis CTSC TL1 Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility MentorshipTL1TR001861 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MEDICI, VALENTINA · 2016 to 2025
$4.7M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
Role of IKCa Channels in Vascular RemodelingR01HL080173 · NHLBI · UNIVERSITY OF NEVADA RENO · PI MIURA, HIROTO · 2007 to 2011
$1.9M
NCATS NIH HHS TL1 TR001861NCATS NIH HHS UL1 TR001860NCRR NIH HHS P20 RR018751NHLBI NIH HHS R01 HL080173NIGMS NIH HHS T32 GM099608
6 · The paper itself

Abstract

Ion channels have recently attracted attention as potential mediators of skin disease. Here, we explored the consequences of genetically encoded induction of the cell volume-regulating Ca2+-activated KCa3.1 channel (Kcnn4) for murine epidermal homeostasis. Doxycycline-treated mice harboring the KCa3.1+-transgene under the control of the reverse tetracycline-sensitive transactivator (rtTA) showed 800-fold channel overexpression above basal levels in the skin and solid KCa3.1-currents in keratinocytes. This overexpression resulted in epidermal spongiosis, progressive epidermal hyperplasia and hyperkeratosis, itch and ulcers. The condition was accompanied by production of the pro-proliferative and pro-inflammatory cytokines, IL-β1 (60-fold), IL-6 (33-fold), and TNFα (26-fold) in the skin. Treatment of mice with the KCa3.1-selective blocker, Senicapoc, significantly suppressed spongiosis and hyperplasia, as well as induction of IL-β1 (-88%) and IL-6 (-90%). In conclusion, KCa3.1-induction in the epidermis caused expression of pro-proliferative cytokines leading to spongiosis, hyperplasia and hyperkeratosis. This skin condition resembles pathological features of eczematous dermatitis and identifies KCa3.1 as a regulator of epidermal homeostasis and spongiosis, and as a potential therapeutic target.

Indexed as

TransgenesAcetamidesAnimalsCytokinesDoxycyclineEczemaEpidermisFemaleHomeostasisHyperplasiaIntermediate-Conductance Calcium-Activated Potassium ChannelsKeratinocytesKeratosisMaleMiceMice, Inbred C57BLAcetamidesCytokinesDoxycyclineIntermediate-Conductance Calcium-Activated Potassium ChannelsKcnn4 protein, mousesenicapocTrans-ActivatorsTriphenylmethyl Compounds

Identifiers

PMID32150577
PMCPMC7062274
OpenAlexW3012445391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.